Biomarkers - Global Strategic Business Report

The global market for Biomarkers was valued at US$108.7 Billion in 2024 and is projected to reach US$235.2 Billion by 2030, growing at a CAGR of 13.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and what they mean for your business.

Biomarkers - Key Trends and Drivers Summarized

Biomarkers have revolutionized healthcare by providing precise tools for disease identification and management, enhancing treatment efficacy, and fostering the development of new drugs. These biological indicators are measurable signals of various biological states or conditions, crucial for diagnosing diseases and monitoring the effectiveness of treatments. Initially, disease detection relied heavily on observable physical symptoms and sample analysis. However, with significant technological advancements over the years, the discovery and development of numerous biomarkers have greatly enriched medical diagnostics and treatment options. This evolution has facilitated earlier and more precise diagnoses, improved treatment strategies, and minimized errors, leading to better and more cost-effective healthcare solutions.

The integration of biomarkers into modern medicine spans various functions, from diagnosing conditions to predicting treatment outcomes. They are classified into categories such as molecular, radiographic, histologic, and physiologic biomarkers, each serving unique roles. For example, molecular biomarkers are found in biological samples like blood and cerebrospinal fluid, indicating molecular interactions and biochemical changes. Radiographic biomarkers, derived from imaging studies, non-invasively assess health conditions, such as bone density. Histologic biomarkers reflect biochemical changes in tissues or cells, crucial for diagnosing and staging cancers. Physiologic biomarkers, like blood pressure or heart rate, provide direct insights into bodily functions. These biomarkers enhance disease management through various stages of healthcare, including diagnostic, prognostic, predictive, and monitoring biomarkers, thereby optimizing patient care and treatment strategies.

The growth of the biomarker field is driven by several factors. Innovations in detection technologies, such as next-generation sequencing, high-throughput screening, and bioinformatics, have enhanced the precision and speed of biomarker analysis, essential for timely and accurate diagnoses. The integration of biomarkers with artificial intelligence (AI) and big data analytics enables sophisticated data analysis, improving disease pattern prediction and treatment outcomes. In the pharmaceutical industry, biomarkers streamline drug development processes and personalize drug therapies, reducing clinical trial time and costs. Advanced diagnostic platforms that leverage biomarkers offer comprehensive health assessments, enhancing their practical utility in clinical settings. Additionally, rising health awareness and preventive medicine trends influence biomarker adoption, as consumers seek personalized healthcare solutions. Increased consumer participation in healthcare decisions and supportive regulatory frameworks further drive the use of biomarker-based tests and therapies. The expansion of insurance coverage for biomarker tests makes these advanced diagnostics more accessible, embedding biomarkers into routine medical practice and advancing modern medical diagnostics and therapeutic strategies.

Report Scope

The report analyzes the Biomarkers market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.

Segments: Type (Safety, Efficacy, Validation); Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Diseases); Application (Drug Discovery & Development, Diagnostics, Personalized Medicines, Other Applications).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Safety segment, which is expected to reach US$89.8 Billion by 2030 with a CAGR of a 13.9%. The Efficacy segment is also set to grow at 12.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $27.7 Billion in 2024, and China, forecasted to grow at an impressive 17.8% CAGR to reach $57.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Biomarkers Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Biomarkers Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Biomarkers Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Molecular, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Epigenomics AG, F. Hoffmann-La Roche AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 282 companies featured in this Biomarkers market report include:

• Abbott Molecular, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• QIAGEN NV
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry